PR99110

MOUNTAIN VIEW, Calif., Dec. 6, 2022 /PRNewswire=KYODO JBN/ --

    -- Data unveiled at four industry conferences suggest a single ERA treatment

       may be more effective than combination therapies used today

    -- Biomarker analysis demonstrates ERA's regenerative impact on fibroblast

       proliferation, collagen VII production

    -- eTurna(TM) lipid-based delivery platform proves groundbreakingly

       effective at reaching targeted tissue

    -- Company to present updated data during January webinar

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, released preliminary

data that show its therapies rejuvenate skin cells more effectively and safely

than existing treatments.

Photo - https://mma.prnewswire.com/media/1962869/ERA_Injected_1.jpg

Logo - https://mma.prnewswire.com/media/1935529/TURN_LOGO_HI_RES_Logo.jpg

The company's ERA(TM) (Epigenetic Reprogramming of Aging) treatment, precisely

transported using Turn Bio's proprietary eTurna(TM) lipid-based delivery

platform, reversed the hallmarks of aging in human skin – something never

before achieved. The treatment simultaneously increased fibroblasts and

collagen VII to restore the production of collagen and elastin, and reduced

inflammation markers, oxidative stress, senescence, and MMPs, proteins

responsible for skin degradation versus those untreated.

Preclinical data were presented to dermatologists and industry KOLs attending

four global conferences in the past five weeks: Global Aesthetics Conference in

Miami; Cosmetic Surgery Forum in Nashville, Tennessee; Beauty Through Science

in New York City, and The Longevity Summit in San Francisco, California.

"The data suggest we may be close to redefining the care dermatologists can

provide their patients," said Jill Waibel, a board-certified dermatologist and

respected regenerative medicine researcher who presented findings at the Global

Aesthetics Conference. "The potential to improve the quality of patients' skin

– its elasticity and its ability to heal – could change the future of

regenerative medicine."

Hema Sundaram, a board-certified dermatologist and noted researcher in

regenerative medicine and cell science, presented the data at Cosmetic Surgery

Forum.

"This early research suggests that ERA could significantly improve the balance

between key biomarkers of cell aging and cell youthfulness," she said. "From an

evidence-based perspective, this carries more weight as a rejuvenation strategy

than efforts to improve a single biomarker. Research of this type may open the

door to a new paradigm of dermatologic care."

Data were also presented during sessions of the Beauty Through Science

conference and the Longevity Summit.

"We believe this promises to be a game-changer for dermatologists, plastic

surgeons and their patients," said Turn Bio CEO Anja Krammer. "The true

breakthrough of combining our mRNA-based ERA therapy with our eTurna lipid

delivery system, for the first time shows reversal from the effects of aging

and offers an ability to improve the overall quality of the skin."

Turn Bio executives have committed to releasing additional data during a

January webinar. Details will be announced in coming weeks.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level and developing transformative drug delivery systems. The

company's proprietary mRNA platform technology, ERA(TM) (Epigenetic

Reprogramming of Aging), restores optimal gene expression by combatting the

effects of aging in the epigenome. This restores cells' ability to prevent or

treat disease and heal or regenerate tissue. It will help to fight incurable

chronic diseases. Its eTurna(TM) Delivery Platform uses unique formulations to

precisely deliver cargo to specific organs, tissues, and cell types

The company is completing pre-clinical research on tailored therapies targeting

indications in dermatology and immunology, and developing therapies for

ophthalmology, osteo-arthritis, and the muscular system. For more information,

see www.turn.bio .

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or +1 (312) 543-9026

SOURCE  Turn Biotechnologies, Inc.